Pacira Pharma (PCRX) Tops Q2 EPS by 20c; offers guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Pacira Pharma (PCRX) Tops Q2 EPS by 20c; offers guidance

Pacira Pharmaceuticals (PCRX) PT Lowered to $30 at Jefferies

August 1, 2024 3:59 PM EDT

Jefferies analyst Glen Santangelo lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $30.00 (from $36.00) while maintaining a Buy rating.

The analyst comments "Updating model to reflect 2Q results. Overall, we think NT results remain overshadowed by the pending court ruling... More

Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital

July 31, 2024 6:24 AM EDT

RBC Capital analyst Daniel Busb lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $37.00 (from $42.00) while maintaining a Outperform rating.

The analyst comments "While PCRX continues to execute on delivering positive Exparel numbers through 1H, focus remains squarely on ongoing patent... More